PALE
MCID: PST092
MIFTS: 29

Posttransplant Acute Limbic Encephalitis (PALE)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Posttransplant Acute Limbic Encephalitis

MalaCards integrated aliases for Posttransplant Acute Limbic Encephalitis:

Name: Posttransplant Acute Limbic Encephalitis 58
Pale 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Orphanet 58 ORPHA163921

Summaries for Posttransplant Acute Limbic Encephalitis

MalaCards based summary : Posttransplant Acute Limbic Encephalitis, also known as pale, is related to clear cell acanthoma and deficiency anemia. The drugs mometasone furoate and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and breast.

Related Diseases for Posttransplant Acute Limbic Encephalitis

Diseases related to Posttransplant Acute Limbic Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 235, show less)
# Related Disease Score Top Affiliating Genes
1 clear cell acanthoma 11.9
2 deficiency anemia 11.3
3 obesity, early-onset, with adrenal insufficiency and red hair 11.2
4 pernicious anemia 11.2
5 oculocutaneous albinism 11.2
6 biliary atresia 11.2
7 hepatitis b 11.2
8 syncope 11.2
9 iron-refractory iron deficiency anemia 11.2
10 anemia, sideroblastic, 1 11.2
11 cardiomyopathy, infantile histiocytoid 11.1
12 glucosephosphate dehydrogenase deficiency 11.1
13 thoracic outlet syndrome 11.1
14 tietz albinism-deafness syndrome 11.0
15 clouston syndrome 11.0
16 optic atrophy 1 11.0
17 pyruvate kinase deficiency of red cells 11.0
18 cyclic vomiting syndrome 11.0
19 alpha-thalassemia 11.0
20 capillary malformation-arteriovenous malformation 1 11.0
21 erythroderma, ichthyosiform, congenital reticular 11.0
22 majeed syndrome 11.0
23 beta-thalassemia 11.0
24 macular dystrophy with central cone involvement 11.0
25 paroxysmal nocturnal hemoglobinuria 11.0
26 thalassemia 11.0
27 lepromatous leprosy 11.0
28 congenital dyserythropoietic anemia 11.0
29 waardenburg's syndrome 11.0
30 hypochromic microcytic anemia with iron overload 11.0
31 methylmalonic acidemia with homocystinuria 11.0
32 alagille syndrome 1 10.9
33 hashimoto thyroiditis 10.9
34 klippel-trenaunay-weber syndrome 10.9
35 systemic lupus erythematosus 10.9
36 chromosome 5q deletion syndrome 10.9
37 motion sickness 10.9
38 noonan syndrome 1 10.9
39 optic atrophy 3, autosomal dominant 10.9
40 paget disease, extramammary 10.9
41 pheochromocytoma 10.9
42 sturge-weber syndrome 10.9
43 atransferrinemia 10.9
44 folate malabsorption, hereditary 10.9
45 glutamate formiminotransferase deficiency 10.9
46 ghosal hematodiaphyseal dysplasia 10.9
47 hemolytic uremic syndrome, atypical 1 10.9
48 thiamine-responsive megaloblastic anemia syndrome 10.9
49 myeloma, multiple 10.9
50 3-methylglutaconic aciduria, type iii 10.9
51 intrinsic factor deficiency 10.9
52 megaloblastic anemia 1 10.9
53 thrombotic thrombocytopenic purpura, congenital 10.9
54 albinism, ocular, with late-onset sensorineural deafness 10.9
55 phosphoglycerate kinase 1 deficiency 10.9
56 anemia, sideroblastic, and spinocerebellar ataxia 10.9
57 pearson marrow-pancreas syndrome 10.9
58 nicolaides-baraitser syndrome 10.9
59 macular degeneration, age-related, 1 10.9
60 basal cell carcinoma 1 10.9
61 3-methylglutaconic aciduria, type v 10.9
62 thiopurines, poor metabolism of, 1 10.9
63 cerebroretinal microangiopathy with calcifications and cysts 1 10.9
64 crouzon syndrome with acanthosis nigricans 10.9
65 acute promyelocytic leukemia 10.9
66 leukemia, acute lymphoblastic 10.9
67 reynolds syndrome 10.9
68 basal cell carcinoma 7 10.9
69 triosephosphate isomerase deficiency 10.9
70 peripheral vascular disease 10.9
71 twin-to-twin transfusion syndrome 10.9
72 alternating hemiplegia of childhood 10.9
73 lymphoblastic lymphoma 10.9
74 desmoid tumor 10.9
75 alpha thalassemia-x-linked intellectual disability syndrome 10.9
76 cholelithiasis 10.9
77 thrombotic thrombocytopenic purpura 10.9
78 cholecystolithiasis 10.9
79 iron deficiency anemia 10.9
80 hereditary spherocytosis 10.9
81 diamond-blackfan anemia 10.9
82 pure red-cell aplasia 10.9
83 familial lipoprotein lipase deficiency 10.9
84 urticaria 10.9
85 alcohol use disorder 10.9
86 benign eccrine breast spiradenoma 10.9
87 hepatitis 10.9
88 clear cell renal cell carcinoma 10.9
89 chromophobe renal cell carcinoma 10.9
90 bile duct cancer 10.9
91 focal epithelial hyperplasia 10.9
92 neuroblastoma 10.9
93 lichen nitidus 10.9
94 evans' syndrome 10.9
95 acquired pure red cell aplasia 10.9
96 atrophic lichen planus 10.9
97 autoimmune atrophic gastritis 10.9
98 bier spots 10.9
99 familial lcat deficiency 10.9
100 familial thoracic aortic aneurysm and dissection 10.9
101 infantile apnea 10.9
102 slc4a1-associated distal renal tubular acidosis 10.9
103 thrombotic thrombocytopenic purpura, acquired 10.9
104 white matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome 10.9
105 ren-related kidney disease 10.9
106 dyserythropoietic anemia and thrombocytopenia 10.9
107 glucose phosphate isomerase deficiency 10.9
108 glycogen storage disease type 0 10.9
109 fainting 10.9
110 shaken baby syndrome 10.9
111 acanthoma 10.3
112 hermansky-pudlak syndrome 10.3
113 malignant hyperthermia 10.2
114 eumycotic mycetoma 10.2
115 leukemia 10.1
116 temporal lobe epilepsy 10.1
117 encephalitis 10.1
118 limbic encephalitis 10.1
119 medulloblastoma 10.1
120 hermansky-pudlak syndrome 1 10.1
121 chops syndrome 10.1
122 iron metabolism disease 10.1
123 dermatitis 10.1
124 adenocarcinoma 10.1
125 cataract 10.1
126 mycetoma 10.1
127 neurofibromatosis, type ii 10.0
128 epidermolytic hyperkeratosis 10.0
129 hepatocellular carcinoma 10.0
130 chediak-higashi syndrome 10.0
131 adenomyosis 10.0
132 autosomal recessive disease 10.0
133 neuroretinitis 10.0
134 keratosis 10.0
135 mammary paget's disease 10.0
136 retinitis 10.0
137 skin disease 10.0
138 myopathy 10.0
139 albinism 10.0
140 dwarfism 10.0
141 erythrokeratoderma ''en cocardes'' 10.0
142 autosomal dominant epidermolytic ichthyosis 10.0
143 breast cancer 9.9
144 optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 9.9
145 hair whorl 9.9
146 malignant hyperthermia 1 9.9
147 neurofibromatosis, type iv, of riccardi 9.9
148 ocular dominance 9.9
149 papillomatosis, confluent and reticulated 9.9
150 parkinson disease, late-onset 9.9
151 polykaryocytosis inducer 9.9
152 keratosis, seborrheic 9.9
153 spherocytosis, type 1 9.9
154 storage pool platelet disease 9.9
155 thyroid cancer, nonmedullary, 1 9.9
156 yunis-varon syndrome 9.9
157 enterocolitis 9.9
158 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
159 hypoascorbemia 9.9
160 nonarteritic anterior ischemic optic neuropathy 9.9
161 phenylketonuria 9.9
162 retinitis pigmentosa 9.9
163 short tarsus with absence of lower eyelashes 9.9
164 leukemia, acute myeloid 9.9
165 autoimmune lymphoproliferative syndrome 9.9
166 branchiootic syndrome 1 9.9
167 meningioma, radiation-induced 9.9
168 nasopharyngeal carcinoma 9.9
169 allergic rhinitis 9.9
170 meningioma, familial 9.9
171 hepatitis c virus 9.9
172 charcot-marie-tooth disease, type 4j 9.9
173 ectodermal dysplasia-syndactyly syndrome 2 9.9
174 lymphedema, primary, with myelodysplasia 9.9
175 myelodysplastic syndrome 9.9
176 dengue virus 9.9
177 reticulate acropigmentation of kitamura 9.9
178 hydrops, lactic acidosis, and sideroblastic anemia 9.9
179 helix syndrome 9.9
180 multinodular goiter 9.9
181 vitamin b12 deficiency 9.9
182 metabolic acidosis 9.9
183 rickets 9.9
184 hypertrophy of breast 9.9
185 dirofilariasis 9.9
186 spinal meningioma 9.9
187 choroiditis 9.9
188 optic neuritis 9.9
189 goiter 9.9
190 pancytopenia 9.9
191 diarrhea 9.9
192 ehlers-danlos syndrome 9.9
193 cholestasis 9.9
194 papilledema 9.9
195 pneumothorax 9.9
196 neuritis 9.9
197 optic nerve disease 9.9
198 coccidiosis 9.9
199 gastroenteritis 9.9
200 neonatal jaundice 9.9
201 sensory peripheral neuropathy 9.9
202 hemangioma 9.9
203 idiopathic interstitial pneumonia 9.9
204 endometriosis 9.9
205 newcastle disease 9.9
206 papillary carcinoma 9.9
207 lysosomal storage disease 9.9
208 pulmonary fibrosis 9.9
209 hidrocystoma 9.9
210 thyroid gland papillary carcinoma 9.9
211 pancreatic adenocarcinoma 9.9
212 mutism 9.9
213 tinea capitis 9.9
214 rhinitis 9.9
215 secretory meningioma 9.9
216 lymphoplasmacyte-rich meningioma 9.9
217 sclerosing hemangioma 9.9
218 kidney disease 9.9
219 inverted follicular keratosis 9.9
220 chronic kidney disease 9.9
221 neuropathy 9.9
222 dermatophytosis 9.9
223 esophageal leukoplakia 9.9
224 hard palate cancer 9.9
225 epiglottitis 9.9
226 follicular mucinosis 9.9
227 hypereosinophilic syndrome 9.9
228 leukoplakia 9.9
229 myxozoa 9.9
230 pili torti 9.9
231 back pain 9.9
232 tremor 9.9
233 adrenogenital syndrome 9.9
234 lymphedema 9.9
235 thyroid carcinoma 9.9

Graphical network of the top 20 diseases related to Posttransplant Acute Limbic Encephalitis:



Diseases related to Posttransplant Acute Limbic Encephalitis

Symptoms & Phenotypes for Posttransplant Acute Limbic Encephalitis

Drugs & Therapeutics for Posttransplant Acute Limbic Encephalitis

Drugs for Posttransplant Acute Limbic Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 213, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Lactulose Approved Phase 4 4618-18-2 11333
5
Sorbitol Approved Phase 4 50-70-4 5780
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Pantoprazole Approved Phase 4 102625-70-7 4679
13
Calcium carbonate Approved, Investigational Phase 4 471-34-1
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
18
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
19
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
20 Opiate Alkaloids Phase 4
21 Liver Extracts Phase 4
22 Antidepressive Agents Phase 4
23 Pharmaceutical Solutions Phase 4
24 Gastrointestinal Agents Phase 4
25 Antiemetics Phase 4
26 Hormone Antagonists Phase 4
27 Autonomic Agents Phase 4
28 Hormones Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Bacterial Agents Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Vaccines Phase 4
33 Reverse Transcriptase Inhibitors Phase 4
34 Anti-Retroviral Agents Phase 4
35 Cathartics Phase 4
36 Anti-HIV Agents Phase 4
37 Laxatives Phase 4
38 Contraceptive Agents Phase 4
39 Norgestimate, ethinyl estradiol drug combination Phase 4
40 Contraceptives, Oral Phase 4
41 Contraceptives, Oral, Combined Phase 4
42 Estradiol 17 beta-cypionate Phase 4
43 Estradiol 3-benzoate Phase 4
44 Dextrans Phase 4
45 Calcium, Dietary Phase 4
46 glucocorticoids Phase 4
47 BB 1101 Phase 4
48 Triamcinolone diacetate Phase 4
49 Ophthalmic Solutions Phase 4
50 triamcinolone acetonide Phase 4
51 Triamcinolone hexacetonide Phase 4
52 Analgesics Phase 4
53 Narcotics Phase 4
54 Anesthetics, Local Phase 4
55 Anesthetics Phase 4
56 Central Nervous System Depressants Phase 4
57 Analgesics, Opioid Phase 4
58 Anesthetics, General Phase 4
59 Adjuvants, Anesthesia Phase 4
60 Anesthetics, Intravenous Phase 4
61 Triiodobenzoic Acids Phase 4
62 Orange Approved Phase 3
63
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
64 Neurotransmitter Agents Phase 3
65 Rho(D) Immune Globulin Phase 3
66 Immunoglobulin G Phase 3
67 gamma-Globulins Phase 3
68 Immunoglobulins, Intravenous Phase 3
69 Hematinics Phase 3
70 Epoetin alfa Phase 3 113427-24-0
71 Imatinib Mesylate Phase 3 220127-57-1 123596
72 Dermatologic Agents Phase 3
73 Anti-Allergic Agents Phase 3
74
Naproxen Approved, Vet_approved Phase 2 22204-53-1 1302 156391
75
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
76
Ichthammol Approved Phase 2 8029-68-3
77
Ranibizumab Approved Phase 1, Phase 2 347396-82-1 459903
78
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
79
Metronidazole Approved Phase 2 443-48-1 4173
80
Oxytetracycline Approved, Investigational, Vet_approved Phase 2 79-57-2 54715139 5280972
81
Nitisinone Approved, Investigational Phase 1, Phase 2 104206-65-7 115355
82
Edetic Acid Approved, Vet_approved Phase 2 62-33-9, 60-00-4 6049
83
Pentetic acid Approved Phase 2 67-43-6
84
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
85
Methyltestosterone Approved Phase 2 58-18-4 6010
86
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
87
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 6013 10204
88
Testosterone enanthate Approved Phase 2 315-37-7 9416
89
nivolumab Approved Phase 2 946414-94-4
90
Ipilimumab Approved Phase 2 477202-00-9
91
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
92
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
93
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
94
Titanium dioxide Approved Phase 2 13463-67-7
95
Povidone Approved Phase 1, Phase 2 9003-39-8
96
Dimenhydrinate Approved Phase 1, Phase 2 523-87-5 441281
97
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
98
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
99
Povidone-iodine Approved Phase 2 25655-41-8
100
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
101
Camptothecin Experimental Phase 2 7689-03-4
102 Analgesics, Non-Narcotic Phase 2
103 Cyclooxygenase Inhibitors Phase 2
104 Anti-Inflammatory Agents, Non-Steroidal Phase 2
105 Antibiotics, Antitubercular Phase 2
106 Respiratory System Agents Phase 2
107 Anti-Asthmatic Agents Phase 2
108 Bronchodilator Agents Phase 2
109 Angiogenesis Inhibitors Phase 1, Phase 2
110 Antimalarials Phase 2
111 Antiparasitic Agents Phase 2
112 Antiprotozoal Agents Phase 2
113 Cytochrome P-450 Enzyme Inhibitors Phase 2
114 Steroid Synthesis Inhibitors Phase 2
115 Estrogens Phase 2
116
Abiraterone acetate Phase 2 154229-18-2 57336518
117 Trace Elements Phase 2
118 Vitamins Phase 2
119 Micronutrients Phase 2
120 Estrogens, Conjugated (USP) Phase 2
121 Protective Agents Phase 2
122 Nutrients Phase 2
123 taxane Phase 2
124 Antioxidants Phase 2
125 Anabolic Agents Phase 2
126 Testosterone 17 beta-cypionate Phase 2
127 Androgens Phase 2
128 Antineoplastic Agents, Immunological Phase 2
129 Monoacetyldapsone Phase 2
130 Protein Kinase Inhibitors Phase 2
131 Aromatase Inhibitors Phase 2
132 Ferrosoferric Oxide Phase 2
133 Butylated Hydroxytoluene Phase 2
134 cadexomer iodine Phase 1, Phase 2
135 Anti-Infective Agents, Local Phase 1, Phase 2
136 topoisomerase I inhibitors Phase 2
137
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
138
Ketoconazole Approved, Investigational Phase 1 65277-42-1 47576
139
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
140
Montelukast Approved Phase 1 158966-92-8 5281040
141
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
142
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
143
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
144
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
145
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 60843 446556
146
belimumab Approved Phase 1 356547-88-1 10451420 5957
147
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
148
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
149
Vitamin D3 Approved, Nutraceutical Phase 1 67-97-0 6221 5280795
150
Casopitant Investigational Phase 1 414910-30-8, 414910-27-3 23725089
151
Lactitol Investigational Phase 1 585-88-6, 585-86-4 493591
152 Antifungal Agents Phase 1
153 Cytochrome P-450 CYP3A Inhibitors Phase 1
154 neurokinin A Phase 1
155 Neurokinin-1 Receptor Antagonists Phase 1
156
Substance P Phase 1 33507-63-0 44359816
157 Adjuvants, Immunologic Phase 1
158 Leukotriene Antagonists Phase 1
159 Mitogens Phase 1
160 Albumin-Bound Paclitaxel Phase 1
161 Antimitotic Agents Phase 1
162
Diethylenetriamine Phase 1 111-40-0 8111
163 MF59 oil emulsion Phase 1
164 Ergocalciferols Phase 1
165 Vitamin D2 Phase 1
166 Calciferol Phase 1
167 Rezafungin Phase 1
168
Histidine Investigational, Nutraceutical Phase 1 71-00-1 6274
169
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
170
acetic acid Approved 64-19-7 176
171
Aminolevulinic acid Approved 106-60-5 137
172
Methamphetamine Approved, Illicit 537-46-2 10836
173
Dopamine Approved 51-61-6, 62-31-7 681
174
Sodium citrate Approved, Investigational 68-04-2
175
tannic acid Approved 1401-55-4
176
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
177
Amoxicillin Approved, Vet_approved 26787-78-0 33613
178
Potassium citrate Approved, Investigational, Vet_approved
179
Rabeprazole Approved, Investigational 117976-89-3 5029
180
Mitoxantrone Approved, Investigational 65271-80-9 4212